<DOC>
	<DOCNO>NCT00929006</DOCNO>
	<brief_summary>The purpose study determine late pubertal girl without hyperandrogenemia ( HA ) , progesterone ( P ) acutely reduce wake lutenizing hormone ( LH ) frequency great extent sleep-associated LH frequency . We hypothesize late pubertal girl HA : ( ) wake sleep-associated LH frequency elevate ( compare control ) ; ( b ) P suppress wake LH frequency lesser degree girl without HA .</brief_summary>
	<brief_title>Time Course Waking Versus Sleep-associated Luteinizing Hormone ( LH ) Pulse Frequency Suppression Response Progesterone Late Pubertal Girls With Without Hyperandrogenemia</brief_title>
	<detailed_description>During early puberty , LH frequency increase sleep ; late puberty , LH frequency decrease overnight . Nonetheless , nocturnal LH frequency similar ( ~0.5 pulse per hour ) early late pubertal girl . Preliminary data early pubertal girl suggest progesterone acutely slow wake LH frequency , acutely change nocturnal LH frequency . We hypothesize daytime LH frequency regulate primarily sex steroid negative feedback , sleep-associated LH frequency ; androgen interfere sex steroid suppression daytime LH frequency . We propose assess use protocol short-term Progesterone placebo give late pubertal girl ( cross-over fashion ) , subsequent assessment LH pulse frequency ( sample occur awake asleep ) . We propose effect Progesterone blunt absent late pubertal girl hyperandrogenemia .</detailed_description>
	<mesh_term>Hyperandrogenism</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<criteria>1 . Late pubertal girl ( Tanner breast stage 3 , 4 , 5 ) 2 . Postmenarcheal , 4 postmenarcheal 3 . Age 1017 1 . Age &lt; 10 &gt; 17 2 . BMIforage &lt; 5th percentile 3 . Inability comprehend do study do 4 . Being study GnRH pulse regulation adolescent girl without HA , boys exclude 5 . Obesity associate diagnosed ( genetic ) syndrome ( e.g. , PraderWilli syndrome , leptin deficiency ) , obesity relate medication ( e.g. , glucocorticoid ) , etc . 6 . Pregnancy lactation 7 . Virilization 8 . Total testosterone &gt; 150 ng/dl 9 . DHEAS &gt; upper limit ageappropriate normal range ( mild elevation may see adolescent HA , elevation &lt; 1.5 time ageappropriate upper limit normal accepted girl ) 10 . 17hydroxyprogesterone &gt; 250 ng/dl , suggest possibility congenital adrenal hyperplasia ( postmenarcheal , 17hydroxyprogesterone collect follicular phase , &gt; 60 oligomenorrheic ) . NOTE : If 17hydroxyprogesterone &gt; 250 ng/dl confirm repeat testing , ACTH stimulate 17hydroxyprogesterone &lt; 1000 ng/dl require study participation 11 . History premature adrenarche ( i.e. , appearance pubic and/or axillary hair age 8 ) 12 . A previous diagnosis diabetes 13 . Fasting glucose â‰¥ 126 mg/dl , hemoglobin A1c &gt; 6.5 % ( confirmed repeat ) 14 . Abnormal TSH ( confirm repeat ) ( subject adequately treat hypothyroidism , reflect normal TSH value , exclude ) 15 . Abnormal prolactin ( confirmed repeat ) ( mild elevation may see HA girl , elevation &lt; 1.5 time upper limit normal accept group ) 16 . Evidence Cushing 's syndrome history physical exam ( e.g. , history impaired growth child , stria ) 17 . Hematocrit &lt; 36 % hemoglobin &lt; 12 g/dl ( specifically , documentation hematocrit &gt; = 36 % hemoglobin &gt; = 12 g/dl month prior GCRC admission require frequent sample protocol GCRC ) 18 . Significant history cardiac pulmonary dysfunction ( e.g. , know suspect congestive heart failure ; asthma require intermittent systemic corticosteroid ; etc . ) 19 . Persistent liver test abnormality ( confirm repeat ) , exception mild bilirubin elevation accept set know Gilbert 's syndrome 20 . Persistently abnormal sodium , potassium , elevate creatinine concentration ( confirmed repeat ) 21 . Bicarbonate concentration &lt; 20 &gt; 30 ( confirm repeat ) 22 . No medication know affect reproductive system , glucose metabolism , lipid metabolism , blood pressure take 3 month prior first inpatient GCRC study ( 2 month prior screen ) . Such medication include oral contraceptive pill , progestin , metformin , glucocorticoid , psychotropics , sympathomimetics/stimulants ( e.g. , methylphenidate ) . Patients take restricted medication exclude unless write permission ( subject discontinue medication ) receive subject 's physician . 23 . Weight &lt; 22 kg absolute exclusion criterion ( ensure safe blood withdrawal ) 24 . Personal history deep venous thrombosis ( DVT ) 25 . Personal history ovarian , endometrial , breast neoplasia</criteria>
	<gender>Female</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>hyperandrogenemia</keyword>
	<keyword>pubertal</keyword>
	<keyword>polycystic ovary syndrome</keyword>
</DOC>